405512-86-9

Basic information

• Product Name: ((1R),(2R),(3S))-3-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)cyclopentane-carboxylic acid
• Synonyms: ((1R),(2R),(3S))-3-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)cyclopentane-carboxylic acid
• CAS NO: 405512-86-9
• Molecular Weight: 464.38
• Mol File: 405512-86-9.mol

Chemical Properties

• CAS DataBase Reference: ((1R),(2R),(3S))-3-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)cyclopentane-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: ((1R),(2R),(3S))-3-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)cyclopentane-carboxylic acid(405512-86-9)
• EPA Substance Registry System: ((1R),(2R),(3S))-3-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)cyclopentane-carboxylic acid(405512-86-9)

Safety Data

• Hazardous Substances Data: 405512-86-9(Hazardous Substances Data)

Upstream product

• 190271-63-7 (1R,2R,3S)-3[(R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-2-(4-fluorophenyl)cyclopentane-1-carboxylic acid methyl ester 
• 459174-07-3 (S)-(-)-methyl 2-(4-fluorophenyl)-3-hydroxycyclopent-1-enecarboxylate 
• 379679-70-6 2-(4-fluorophenyl)-1,3-cyclopentanedione 
• 379679-64-8 methyl 2-(4-fluorophenyl)-3-oxo-1-cyclopent-1-enecarboxylate 
• 379679-62-6 3-bromo-2-(4-fluorophenyl)-2-cyclopenten-1-one 
• 368-63-8 (R)-[3,5-bis(trifluoromethyl)phenyl]ethanol 
• 352-33-0 1-Chloro-4-fluorobenzene 
• 3859-41-4 1,3-cyclopentadione 
• 190269-75-1 methyl (1R,2R,3S)-2-(4-fluorophenyl)-3-hydroxycyclopentane-1-carboxylate 
• 190269-78-4 (1R,2R,3S)-2-(4-fluorophenyl)-3-hydroxycyclopentane-1-carboxylic acid 
• 30071-93-3 3,5-bis(trifluoromethyl)phenyl methyl ketone 
• 68120-60-5 1-(3,5-bis(trifluoromethyl)phenyl)ethan-1-ol 
• 190269-66-0 1-[3,5-bis(trifluoromethyl)phenyl]ethyl 2,2,2-trichloroethaneimidate 
• 849674-12-0 (1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl-2,2,2-trichloroethanimidoate 

Downstream Products

• 960364-46-9 C₄₁H₃₆F₇NO₆ 
• 871589-73-0 ((1S),(2R),(3R))-1-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)-3-((1R)-1-(benzyloxycarbonylamino)pent-4-en-1-yl)cyclopentane 
• 871589-72-9 ((1S),(2R),(3R))-1-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)-3-((1S)-1-(benzyloxycarbonylamino)pent-4-en-1-yl)cyclopentane 
• 871589-69-4 C₂₆H₂₈F₇NO 
• 871589-84-3 (3R,5R)-5-(((1R),(2R),(3S))-3-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)cyclopentan-1-yl)-1,3-dibenzyloxycarbonyl-3-methylpyrrolidin-2-one 
• 871589-85-4 (3R,5R)-5-(((1R),(2R),(3S))-3-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)cyclopentan-1-yl)-3-carboxy-3-methylpyrrolidin-2-one 
• 871589-71-8 ((1S),(2R),(3R))-3-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)-ethoxy)-2-(4-fluorophenyl)-3-(1-oxopent-4-en-1-yl)cyclopentane 
• 405512-89-2 ((1R),(2R),(3S))-3-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)cyclopentanecarboxaldehyde 

Relevant articles and documents

PROCESS FOR MAKING LACTAM TACHYKININ RECEPTOR ANTAGONISTS

The present invention is directed to a process for preparing certain α,α disubstituted γ-lactam derivatives that are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The compounds are useful i

COMBINATION THERAPY FOR THE TREATMENT OF URINARY FREQUENCY, URINARY URGENCY AND URINARY INCONTINENCE

This invention concerns compositions for the treatment of urinary frequency, urinary urgency and urinary incontinence comprising a selected antagonist of the NK-1 receptor or a pharmaceutically acceptable salt thereof and an anti-muscarinic agent or a pha

Cyclopentane-based human NK1 antagonists. Part 2: Development of potent, orally active, water-soluble derivatives

The synthesis and optimization of a cyclopentane-based hNK1 antagonist scaffold 3, having four chiral centers, will be discussed in the context of its enhanced water solubility properties relative to the marketed anti-emetic hNK1 antagonist EMEND (Aprepitant). Sub-nanomolar hNK1 binding was achieved and oral activity comparable to Aprepitant in two in vivo models will be described.

Lactam tachykinin receptor antagonists

The present invention is directed to certain lactam compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations compri